ClinicalThe late-stage research of Bristol Myers' heart disease medication...

The late-stage research of Bristol Myers’ heart disease medication falls short of its primary objectives

-

Bristol Myers Squibb disclosed that its drug stavartanate did not successfully improve functional capacity or symptom intensities in heart disease patients, thus failing to reach the primary study targets.
Mavacamten received testing in adults suffering from the non-obstructive form of hypertrophic cardiomyopathy (nHCM), which represents a genetic heart condition featured by heart muscle wall thickening.
The disease HCM affects one out of every twenty adults around the world, while standing as the main identified reason for sudden cardiac death among healthy young Americans, based on government statistics. Camzyos represents a medication previously approved by the U.S. to treat obstructive hypertrophic cardiomyopathy, which creates heart ventricle blockage.

The trial outcome indicates problems with clinical benefit demonstration for less severe patient groups, according to BMO Capital Markets’ analyst Evan Seigerman, as it intensifies pressure for positive developments in upcoming events to move the BMY performance forward.
The clinical trial assessment revealed no safety warnings had appeared to the drug manufacturer. Camzyos carries a warning label with a boxed note due to heart failure risks, according to the strict provisions from the Food and Drug Administration.
The clinical research involved 580 symptomatic patients with nHCM and incorporated their self-reported questionnaire to monitor their medical status, including both symptom occurrence and physical-social constraints.
During 48 weeks of treatment, Mavacamten did not enhance exercise capacity among patients according to peak oxygen use measurements in the study. The company indicated that it will publish comprehensive trial results aimed at scientific experts at a future date.

Life Sciences Voice Logo mobile
+ posts

Latest news

Definium Bags Major Phase 3 Victory With LSD Formula

Definium Therapeutics has scored another phase 3 success with its LSD-based therapy, this time demonstrating positive results in generalized...

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

New research involving infant macaques has produced findings that may support further investigation of CytoDyn’s CCR5-targeting antibody leronlimab in...

Why Data Is Becoming Pharma’s Most Valuable Asset

Pharma's:Executive Summary For decades, pharmaceutical companies have built competitive advantage around scientific expertise, intellectual property, manufacturing capabilities, commercial reach, and...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you